Scinovex
review Open AccessTop 1% cited

Aβ Oligomers – a decade of discovery

Journal of Neurochemistry · 2007 · Vol. 101(5) · pp. 1172–1184
Dominic M. WalshDennis J. Selkoe

Abstract

Converging lines of evidence suggest that progressive accumulation of the amyloid beta-protein (A beta) plays a central role in the genesis of Alzheimer's disease, but it was long assumed that A beta had to be assembled into extracellular amyloid fibrils to exert its cytotoxic effects. Over the past decade, data have emerged from the use of synthetic A beta peptides, cell culture models, beta-amyloid precursor protein transgenic mice and human brain to suggest that pre-fibrillar, diffusible assemblies of A beta are also deleterious. Although the precise molecular identity of these soluble toxins remains unsettled, accumulating evidence suggests that soluble forms of A beta are indeed the proximate effectors of synapse loss and neuronal injury. Here we review recent progress in understanding the role of soluble oligomers in Alzheimer's disease.

Alzheimer's disease research and treatmentsCholinesterase and Neurodegenerative DiseasesComputational Drug Discovery MethodsEffectorAmyloid (mycology)BiologyNeuroscienceGenetically modified mouseExtracellularFibrilCell biologyAlzheimer's diseaseTransgene

MeSH terms

Alzheimer DiseaseHumansMaleAmyloid beta-PeptidesAmyloid beta-Protein PrecursorProtein Structure, Secondary

Funding

  • Foundation for Neurologic Diseases
  • Wellcome Trust
  • National Institutes of Health
Citations
1,905
FWCI
68.28
field-weighted impact
References
147
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.